Our commitment to you
The StimRouter Reimbursement Group is committed to collaborating with healthcare professionals and patients to navigate through the reimbursement process. We offer a wide array of information and resources to providers that will assist in their efforts to secure benefit coverage and appropriate payment. To speak to someone directly call 800.211.9136 (option 2).
StimRouter PNS coverage
Peripheral Nerve Stimulation with the StimRouter Neuromodulation System is reimbursed nationally by Medicare as a treatment for chronic pain of a peripheral origin. There are many private payers who cover PNS for chronic pain on a national or local level. For more information, contact the StimRouter reimbursement group.
Downloads for PNS coding and prior authorization
We’re committed to helping you secure reimbursement for PNS within your practice. We’ve developed tools to make the process smoother including:
Tel: 800.211.9136, option 2
Monday – Friday, 7 am – 5 pm PST
StimRouter Neuromodulation System, developed, manufactured and sold by Bioness Inc. is cleared by the FDA to treat chronic pain of peripheral nerve origin. StimRouter is a minimally invasive device, consisting of an implanted lead, external pulse transmitter (EPT) and conductive electrode, controlled by a small, hand-held patient programmer. StimRouter is programmed at the direction of the physician to meet patient requirements. Bioness provides this information for your convenience only. It is the responsibility of the provider to determine coverage and to manage billing codes, including modifiers, and charges for the rendered service. Bioness provides assistance for FDA-cleared indications under 510(k) K142432, K190047 and K200482 only. The information provided is subject to change as government policies get modified. It is our understanding that many payers currently do not require a documented psychological evaluation as a prerequisite for coverage of a peripheral nerve stimulator (PNS) implant for pain. However, there may be exceptions and differences based on individual payer and plan policies. Additionally, not all payers have formal, written coverage policies concerning PNS therapies. Therefore, we recommend that providers verify payer coverage policy requirements and seek pre-authorization on an individual patient basis.